IT HAS POWERFUL INHIBITORY ACTION ON THROMBOXANE SYNTHETASE. THE DRUG SUPPRESSES PRODUCTION OF THROMBOXANE A2 WHICH ACTS TO AGGRAVATE AIRWAY OBSTRUCTION.
SODIUM OZAGREL IS CONSIDERED TO DECREASE PLATELET AGGREGATION AND INCREASE CEREBRAL BLOOD FLOW BY DECREASING THROMBOXANE A2, WHICH HAS A PLATELET-AGGREGATING AND A VASOCONSTRICTING ACTION. SODIUM OZAGREL IS CONSIDERED TO BE EFFECTIVE IN THE ACUTE PHASE OF LACUNAR INFARCTION.